Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30302088 | 0.89 | MGLL (0.46) | GPR119NAMPTCYP2C9MGLLUSP30 | |
| SCHEMBL20566947 | 0.89 | MGLL (0.46) | GPR119NAMPTCYP2C9MGLLUSP30 | |
| SCHEMBL25487291 | 0.85 | MGLL (0.45) | GPR119MGLLHCRTR1HCRTR2 | |
| SCHEMBL25487292 | 0.82 | MGLL (0.34) | GPR119MGLLHCRTR1HCRTR2 | |
| SCHEMBL25487285 | 0.80 | GPR119 (0.41) | GPR119NAMPTCYP2C9LMNAMGLL | |
| SCHEMBL25829826 | 0.79 | MGLL (0.47) | MGLL | |
| SCHEMBL25487279 | 0.79 | MGLL (0.54) | MGLL | |
| SCHEMBL25487289 | 0.77 | SRC (0.33) | — | |
| SCHEMBL20571133 | 0.77 | MGLL (0.47) | CYP2C9MGLLPKMHCRTR1HCRTR2 | |
| SCHEMBL20567198 | 0.76 | MGLL (0.55) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | GPR119 308/4885NAMPT 1120/4885CYP2C9 429/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | GPR119 353/4885NAMPT 1243/4885CYP2C9 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.